Ashland ASH executive awarded RSUs and SARs in Form 4 filing

Rhea-AI Filing Summary

Ashland Inc. (ASH) reported an equity compensation grant to a senior executive. On 11/19/2025, the company granted its SVP and GM, Life Sciences, 6,136 Restricted Stock Units (RSUs), each representing one share of Ashland common stock. These RSUs vest in three equal installments starting one year from the grant date, as long as the executive remains continuously employed.

On the same date, the executive also received 13,807 Stock Appreciation Rights (SARs) with an exercise price of $50.58 per share. These SARs become exercisable ratably over three years beginning on the first anniversary of the grant and expire on 11/19/2035. The filing reflects ongoing use of Ashland’s shareholder‑approved incentive compensation plans.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Assis Alessandra Faccin

Role SVP and GM, Life Sciences

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	6,136	$0.00	--
Grant/Award	Stock Appreciation Rights	13,807	$0.00	--

Holdings After Transaction: Restricted Stock Units — 6,136 shares (Direct); Stock Appreciation Rights — 13,807 shares (Direct)

Footnotes (1)

1. Each Restricted Stock Unit (RSU) represents a right to receive one (1) share of ASH Common Stock. Grant of Restricted Stock Units on November 19, 2025, pursuant to Ashland's incentive plan as approved by the shareholders and exempt pursuant to Rule 16b-3. The shares in this grant vest in three equal installments beginning one year from the date of grant, provided that the Reporting Person remains in continuous employment with the issuer. Stock Appreciation Rights (SARs) granted under the Ashland Inc. 2021 Omnibus Incentive Compensation Plan. SARs become exercisable ratably over three years beginning on the first anniversary from the date of grant.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Assis Alessandra Faccin

(Last) (First) (Middle)

8145 BLAZER DRIVE

(Street)

WILMINGTON DE 19808

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ASHLAND INC. [ ASH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP and GM, Life Sciences

3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	11/19/2025		A		6,136		(2)	(2)	Common Stock	6,136	$0	6,136	D
Stock Appreciation Rights(3)	$50.58	11/19/2025		A		13,807		(4)	11/19/2035	Common Stock	13,807	$0	13,807	D

Explanation of Responses:

1. Each Restricted Stock Unit (RSU) represents a right to receive one (1) share of ASH Common Stock.

2. Grant of Restricted Stock Units on November 19, 2025, pursuant to Ashland's incentive plan as approved by the shareholders and exempt pursuant to Rule 16b-3. The shares in this grant vest in three equal installments beginning one year from the date of grant, provided that the Reporting Person remains in continuous employment with the issuer.

3. Stock Appreciation Rights (SARs) granted under the Ashland Inc. 2021 Omnibus Incentive Compensation Plan.

4. SARs become exercisable ratably over three years beginning on the first anniversary from the date of grant.

	/s/ Serena S. Kenost, Attorney-in-Fact for Assis Alessandra Faccin	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Ashland Inc. (ASH) disclose in this Form 4 filing?

Ashland Inc. reported that its SVP and GM, Life Sciences received 6,136 Restricted Stock Units and 13,807 Stock Appreciation Rights as equity compensation on 11/19/2025.

How many RSUs were granted in the Ashland (ASH) Form 4?

The executive received 6,136 Restricted Stock Units (RSUs), each representing the right to receive one share of Ashland common stock.

What Stock Appreciation Rights (SARs) were granted by Ashland (ASH)?

Ashland granted 13,807 Stock Appreciation Rights (SARs) with an exercise price of $50.58 per share, expiring on 11/19/2035.

What is the vesting schedule for the Ashland (ASH) RSUs?

The 6,136 RSUs vest in three equal installments beginning one year from the 11/19/2025 grant date, if the executive remains continuously employed.

When do the Ashland (ASH) SARs become exercisable?

The 13,807 SARs become exercisable ratably over three years, beginning on the first anniversary of the 11/19/2025 grant date.

Under which plan were the Ashland (ASH) RSUs and SARs granted?

The RSUs and SARs were granted under Ashland’s shareholder-approved incentive plans, including the Ashland Inc. 2021 Omnibus Incentive Compensation Plan, and are exempt pursuant to Rule 16b-3.